
EGFR 1G and 2G TKI treatment
Tumor carrying sensitizing mutations
Resistance
acquired resistance alterations
Genome-wide Hypomethylation
Genome instability (CNA changes)
Cancer progression
Regional Hypermethylation
Inhibition of tumor suppressor genes
fewer methylation alterations
sensitizing mutation (del19/L858R)
T790M
EGFR amplification
drug responsive sensitizing mutations
MET or HER2 amplification